Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Diagnosis of recurrent squamous cell carcinomas with the tumor marker SCC-antigen.
Autore:
Arlt, A; Luckhaupt, H; Hildmann, H;
Indirizzi:
Prosper Hosp, Klin Hals Nasen Ohrenheilkunde Kopf & Halschirurg, D-45659 Recklinghausen, Germany Prosper Hosp Recklinghausen Germany D-45659 5659 Recklinghausen, Germany
Titolo Testata:
LARYNGO-RHINO-OTOLOGIE
fascicolo: 4, volume: 79, anno: 2000,
pagine: 207 - 212
SICI:
1615-0007(200004)79:4<207:DORSCC>2.0.ZU;2-I
Fonte:
ISI
Lingua:
GER
Soggetto:
NECK-CANCER; CARCINOEMBRYONIC ANTIGEN; TRYPSIN-INHIBITOR; CERVICAL-CANCER; FOLLOW-UP; HEAD; SERUM; THERAPY; TA-4; CEA;
Keywords:
squamous cell carcinoma (SCC); head and neck; follow-up; neoplasm recurrence; tumor marker; antigens; SCC-antigen; squamous cell carcinoma associated antigen (SCC-Ag);
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Arlt, A Prosper Hosp, Klin Hals Nasen Ohrenheilkunde Kopf & Halschirurg, Muhlenstr27, D-45659 Recklinghausen, Germany Prosper Hosp Muhlenstr 27 Recklinghausen Germany D-45659 Germany
Citazione:
A. Arlt et al., "Diagnosis of recurrent squamous cell carcinomas with the tumor marker SCC-antigen.", LARY RH OTO, 79(4), 2000, pp. 207-212

Abstract

Background: The follow-up of squamous cell carcinomas of the head and neckis often challenging. Due to tissue alteration and anatomic changes after primary treatment or submucosal tumor growth, recurrences are sometimes detected very late. The tumor marker SCC-Antigen (SCC-Ag) may provide additional information for early detection of such tumor recurrences. Patients: Serum levels of SCC-Ag in 578 patients with primary squamous cell carcinomas of the head and neck were assayed by SCC-RIA and IMx-SCC before treatment and every 2-3 months during follow-up. During the observation period of 30-84(mean 50) months, 179 recurrences were verified by histologic examination. Results: Seventy-seven patients (43 %) with tumor recurrence showed elevated serum levels of SCC-Ag (< 2.0 ng/ml). Fifty-eight (32 %) of them exhibited elevated levels of SCC-Ag up to 11 months (mean 6.1 months) prior to histopathologic diagnosis. This mainly became evident in 48 (83%) patients whose SCC-Ag serum levels were elevated before treatment. Conclusion: Use of SCC-Antigen in head and neck tumors follow-up can provide early evidence of almost one third of all recurrences of squamous cell carcinomas of the headand neck. For clinical purposes, we recommend an initial analysis of the SCC-Ag serum level in every patient with primary squamous cell carcinoma of the head and neck. The SCC levels of all SCC positive patients should be closely monitored. Elevated SCC should be regarded as a potential early sign for recurrence and therefore indicates the need for intensified follow-up. Depending on the individual situation this should include ultrasonography, CT, MRI and especially frequent endoscopy in general anesthesia with multiple biopsies of suspicious regions.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 19:32:54